CGIX - Cancer Genetics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2590
+0.0150 (+6.15%)
As of 3:37PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2440
Open0.2600
Bid0.2601 x 3000
Ask0.2644 x 1200
Day's Range0.2440 - 0.2779
52 Week Range0.2000 - 2.2000
Volume2,521,689
Avg. Volume943,927
Market Cap7.181M
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.9430
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 hours ago

    Cancer Genetics Issues Letter to Shareholders

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders from its Chief Executive Officer, Jay Roberts. Happy New Year – we are pleased to provide an update on our activities and strategic development.  We believe that 2018 was an important time for re-assessing our corporate direction, consolidating our company operations and focusing our capabilities in our biopharma business to execute our restructuring, while focusing on revenue growth and accelerating our path to profitability.

  • GlobeNewswire2 days ago

    Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced underwritten public offering of 13,333,334 shares of its common stock ("Common Stock") at a public offering price of $0.225 per share. The Company has also granted the underwriter an option for 45 days to purchase an additional 2,000,000 shares, at a price to the public of $0.225 per share.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • GlobeNewswire7 days ago

    Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $0.225 per share. Cancer Genetics also granted the underwriter a 45-day option to purchase up to an additional 2,000,000 shares of its common stock at the public offering price of $0.225 per share, less underwriting discounts and commissions. Cancer Genetics expects to receive aggregate gross proceeds of approximately $3.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.

  • GlobeNewswire7 days ago

    Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Cancer Genetics also expects to grant the underwriter a 45-day option to purchase additional shares of its common stock to cover over-allotments, if any. Cancer Genetics intends to use the net proceeds from this offering to pay lender fees and other costs incurred in connection with the potential forbearance agreements we are negotiating with our banks, to pay certain costs previously incurred by us in connection with our terminated transaction with NovellusDx Ltd., and if any proceeds remain available, to fund working capital and other general corporate purposes.

  • GlobeNewswire7 days ago

    Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of William Finger as the Company’s Executive Vice President, Precision Medicine and Biopharma Solutions, effective immediately. Mr. Finger will be responsible for developing and overseeing Cancer Genetics’ Precision Medicine and Biopharma and Clinical Trial business unit.

  • GlobeNewswirelast month

    Cancer Genetics Terminates Proposed Merger with NovellusDx

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it has terminated the previously-announced merger agreement with NovellusDx, effective immediately. As a result of the termination of the merger agreement, the Company will pursue alternative strategic and financial transactions with the goal of enhancing shareholder value.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / Biotech stocks Adial Pharmaceuticals and Cancer Genetics were exploding in Thursday’s session. Adial moved higher on news that the company is considering expanding AD04 to treat opioid use disorder. Shares of Cancer Genetics had no news to explain its dramatic share price jump.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates

    Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Cancer Genetics: 3Q Earnings Snapshot

    On a per-share basis, the Rutherford, New Jersey-based company said it had a loss of 31 cents. Losses, adjusted for restructuring costs and costs related to mergers and acquisitions, came to 23 cents per ...

  • GlobeNewswire2 months ago

    Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates

    RUTHERFORD, N.J., Nov. 19, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular.

  • GlobeNewswire2 months ago

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing Cancer Genetics to pursue other opportunities. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability.

  • Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

    Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire4 months ago

    Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (CGIX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.

  • PR Newswire4 months ago

    Chardan Advises NovellusDX in Cross-Border Biotech Merger

    NEW YORK , Sept. 18, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CGIX earnings conference call or presentation 14-Aug-18 12:30pm GMT

    Q2 2018 Cancer Genetics Inc Earnings Call

  • Associated Press5 months ago

    Cancer Genetics: 2Q Earnings Snapshot

    The Rutherford, New Jersey-based company said it had a loss of 13 cents per share. The diagnostics company posted revenue of $7 million in the period. The company's shares closed at 98 cents. A year ago, ...